Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Dec 2024 value amounting to -$2.06.

  • Centessa Pharmaceuticals' EPS (Weighted Average and Diluted) fell 10.81% to -$0.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.90, marking a year-over-year decrease of 25.00%. This contributed to the annual value of -$2.06 for FY2024, which is 31.21% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$2.06 for FY2024, which was down 31.21% from -$1.57 recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of -$1.57 during FY2023, and its lowest value of -$5.07 during FY2021.
  • In the last 3 years, Centessa Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$2.06 in 2024 and averaged -$1.98.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first spiked by 54.44% in 2022, then slumped by 31.21% in 2024.
  • Centessa Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$5.07 in 2021, then soared by 54.44% to -$2.31 in 2022, then surged by 32.03% to -$1.57 in 2023, then slumped by 31.21% to -$2.06 in 2024.